A trial of aleglitazar to improve cardiovascular outcomes in patients with type 2 diabetes who had recent-onset acute coronary syndrome has been terminated early because of a lack of efficacy and an...

Field of Interest: Cardiology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness